All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Treatment sequencing for anemic myelofibrosis
with Jean-Jacques Kiladjian & Angela Fleischman
Monday, February 26, 2024 | 16:30 CET
This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
Bookmark this article
Patients diagnosed with essential thrombocythemia (ET) experience thrombocytosis and risk reduction is therefore a key goal for therapeutic intervention. Currently, the main risk stratification model as recommended by the European LeukemiaNet is the International Prognostic Score of thrombosis in ET (IPSET-t); however, to date there has been no specific tool developed to aid in the prediction of hemorrhagic risk. Below, we summarize a publication from Tosoni et al. in Annals of Hematology on a retrospective analysis to define both the incidence and risk factors connected to hemorrhagic events in patients with ET.
ASH 2022 abstracts: What’s hot in MPN?
To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee members provided their recommendations for the top...
Essential thrombocythemia is associated with a higher risk of thrombosis during COVID-19
COVID-19 has been reported to damage multiple organ systems, primarily the respiratory system, which contributes to the high mortality rate among patients. In...
Subscribe to get the best content related to MPN delivered to your inbox